CN1993313A - 抗菌化合物 - Google Patents
抗菌化合物 Download PDFInfo
- Publication number
- CN1993313A CN1993313A CNA2005800166190A CN200580016619A CN1993313A CN 1993313 A CN1993313 A CN 1993313A CN A2005800166190 A CNA2005800166190 A CN A2005800166190A CN 200580016619 A CN200580016619 A CN 200580016619A CN 1993313 A CN1993313 A CN 1993313A
- Authority
- CN
- China
- Prior art keywords
- compound
- streptomycete
- culture
- bacterial strain
- atcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 53
- 230000003115 biocidal effect Effects 0.000 title description 7
- 238000000034 method Methods 0.000 claims description 17
- 241001655322 Streptomycetales Species 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 abstract description 9
- 241000186394 Eubacterium Species 0.000 abstract description 5
- 238000000855 fermentation Methods 0.000 abstract description 4
- 230000004151 fermentation Effects 0.000 abstract description 4
- 241000187180 Streptomyces sp. Species 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 230000001580 bacterial effect Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 16
- 241000191967 Staphylococcus aureus Species 0.000 description 13
- 229920001817 Agar Polymers 0.000 description 11
- 235000010419 agar Nutrition 0.000 description 10
- 230000000845 anti-microbial effect Effects 0.000 description 10
- 239000002054 inoculum Substances 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000001974 tryptic soy broth Substances 0.000 description 9
- 241000193998 Streptococcus pneumoniae Species 0.000 description 8
- 241000187747 Streptomyces Species 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 238000005497 microtitration Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 239000012266 salt solution Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 241000194032 Enterococcus faecalis Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000606768 Haemophilus influenzae Species 0.000 description 4
- 244000046052 Phaseolus vulgaris Species 0.000 description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940032049 enterococcus faecalis Drugs 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 229940047650 haemophilus influenzae Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000011146 sterile filtration Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010050327 trypticase-soy broth Proteins 0.000 description 4
- 239000012137 tryptone Substances 0.000 description 4
- UQZSVIGPZAULMV-DKWTVANSSA-N (2s)-2,4-diamino-4-oxobutanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)[C@@H](N)CC(N)=O UQZSVIGPZAULMV-DKWTVANSSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000007330 chocolate agar Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- -1 hydroxide amine Chemical class 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910017053 inorganic salt Inorganic materials 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000003592 new natural product Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000011218 seed culture Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- CDAISMWEOUEBRE-SHFUYGGZSA-N 1L-chiro-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O CDAISMWEOUEBRE-SHFUYGGZSA-N 0.000 description 2
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 101000610620 Homo sapiens Putative serine protease 29 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 206010048723 Multiple-drug resistance Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 102100040345 Putative serine protease 29 Human genes 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- 239000006159 Sabouraud's agar Substances 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 229960003907 linezolid Drugs 0.000 description 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 239000012449 sabouraud dextrose agar Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 229960003487 xylose Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GMKMEZVLHJARHF-WHFBIAKZSA-N LL-2,6-diaminopimelic acid Chemical compound OC(=O)[C@@H](N)CCC[C@H](N)C(O)=O GMKMEZVLHJARHF-WHFBIAKZSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 101100397225 Schizosaccharomyces pombe (strain 972 / ATCC 24843) isp3 gene Proteins 0.000 description 1
- 101100397226 Schizosaccharomyces pombe (strain 972 / ATCC 24843) isp4 gene Proteins 0.000 description 1
- 101100397227 Schizosaccharomyces pombe (strain 972 / ATCC 24843) isp5 gene Proteins 0.000 description 1
- 101100397229 Schizosaccharomyces pombe (strain 972 / ATCC 24843) isp7 gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- 238000010564 aerobic fermentation Methods 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000003965 capillary gas chromatography Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical class C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 229940049547 paraxin Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 1
- 229940076156 streptococcus pyogenes Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/609—Amides, e.g. salicylamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
成分 | g/L |
可溶性淀粉 | 20 |
葡萄糖 | 10 |
E型NZ胺 | 5 |
Difco牛肉提取物 | 3 |
Bacto(Difco)蛋白胨 | 5 |
Difco酵母提取物 | 5 |
CaCO3 | 1 |
培养基成分 | g/L |
*Difco酵母提取物 | 6 |
*麦芽提取物 | 15 |
*葡萄糖 | 6 |
微量元素 | 5ml |
MOPS | 20 |
MW | 425 |
MF | C24H27NO6 |
HEESIFTMS | 实测值:426.1911;计算值M+H:426.1911 |
[α]23 D | +2.1°(c0.96,CH3OH) |
UV(CH3OH)λmax | 226(ε16,837)296(2,663)nm |
C5D5N | C5D5N | ||
# | 13C | 类型 | 1H |
1 | 175.2 | C° | |
2 | 32.2 | CH2 | 2.70,m |
3 | 31.8 | CH2 | 2.53,m1.92,m |
4 | 48.1 | C° | |
5 | 204.1 | C° | |
6 | 126.8 | CH | 5.92,d,10.0 |
7 | 154.9 | CH | 6.36,d,10.0 |
8 | 36.7 | C° | |
9 | 40.4 | CH | 2.00,t,10.2 |
10 | 27.1 | CH2 | 1.60,m1.36,brt,10.2 |
11 | 36.6 | CH | 2.26,m |
12 | 26.5 | CH2 | 1.78,m1.56,m |
13 | 28.5 | CH2 | 1.56,t,7.81.80,m |
14 | 44.9 | CH | 1.93,d,10.22.15,d,10.2 |
15 | 149.8 | C° | |
16 | 107.8 | CH2 | 4.71,brs4.87,brs |
17 | 21.5 | CH3 | 1.09,s |
1’ | 175.2 | C° | |
2’ | 107.6 | C° | |
3’ | 158.8 | C° | |
4’ | 115.8 | C° | |
5’ | 158.3 | C° | |
6’ | 110.4 | CH | 6.88,d,8.4 |
7’ | 129.8 | CH | 8.12,d,8.4 |
8’ | NH | 10.50,s |
3’-OH | |||
5’-OH |
培养基 | 生长量 | 气生菌丝体 | 可溶色素 | 基质菌丝体 |
酵母提取物麦芽提取物(ISP2) | 大量 | 发白的灰色(5E1/5E2),大量气生菌丝体具有短而紧密的不规则孢子链,形成环和卷。担子体生长于主要和次要气生分枝中,接合 | 无 | 带黄色的棕色(5D7) |
燕麦粉(ISP3) | 大量 | 灰色(5E2/F2),大量气生菌丝体,紧密盘绕的孢子链的接合 | 无 | 橄榄棕色(4E3) |
无机盐淀粉(ISP4) | 大量 | 带灰色的棕色(5D3/F3),大量气生菌丝体,链的接合 | 无 | 浅黄色(4E3) |
甘油天冬酰胺(ISP5) | 稀疏 | 无 | 无 | 带灰色的橙色(5B4),无性基质菌丝体 |
酪氨酸琼脂(ISP7) | 大量 | 橙灰色(5B2),大量气生菌丝体生长,气生菌丝中短而紧密的螺旋,在接合和结节中断裂 | 无 | 茶褐色(6F7) |
脂肪酸 | 总脂肪酸的% |
14:0异 | 5.66 |
15:0异 | 20.43 |
15:0反异 | 12.43 |
15:0反异2OH | 8.00 |
15:0 | 3.48 |
16::0 | 2.52 |
16:0异 | 17.94 |
16:1异H | 3.54 |
16:0异2OH | 1.14 |
17:0反异 | 3.58 |
17:0环 | 1.48 |
17:0异 | 3.36 |
17:0异C | 2.28 |
17:1反异C | 2.28 |
碳源 | 生长水平 |
D-葡萄糖 | 2 |
L-阿拉伯糖 | 0 |
蔗糖 | 3 |
D-木糖 | 3 |
L-肌醇 | 2 |
D-甘露醇 | 2 |
D-果糖 | 3 |
鼠李糖 | 0 |
棉子糖 | 3 |
纤维素 | 0 |
代表菌株的条件和接种 |
芽胞杆菌、葡萄球菌,培养条件,35℃;在18-22小时阅读MIC;肠球菌:埃希氏菌:阳离子调节的Muller Hinton(CAMHB;BBL);接种=105CFU/mL |
肺炎链球菌:培养条件,35℃;在22-24小时阅读MIC阳离子调节的Muller Hinton+2.5%裂解的马血(LHB);接种=105CFU/mL |
流感嗜血菌:培养条件,35℃;在18-22小时阅读MIC嗜血测试培养基(HTM;Remel);接种=105CFU/mL |
培养条件,35℃;在24小时阅读MIC;RPMI 1640培养基(BioWhittaker)接种=105CFU/mL |
Claims (7)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57389904P | 2004-05-24 | 2004-05-24 | |
US60/573,899 | 2004-05-24 | ||
PCT/US2005/017832 WO2005115400A2 (en) | 2004-05-24 | 2005-05-20 | Antibiotic compound |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1993313A true CN1993313A (zh) | 2007-07-04 |
CN1993313B CN1993313B (zh) | 2012-07-04 |
Family
ID=35451390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800166190A Active CN1993313B (zh) | 2004-05-24 | 2005-05-20 | 抗菌化合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7807445B2 (zh) |
EP (1) | EP1756034B1 (zh) |
JP (1) | JP4541405B2 (zh) |
CN (1) | CN1993313B (zh) |
AU (1) | AU2005247434B2 (zh) |
CA (1) | CA2565431C (zh) |
WO (1) | WO2005115400A2 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2946778A1 (en) * | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2891091A (en) * | 1957-06-03 | 1959-06-16 | Canadian Patents Dev | Derivatives of para-aminosalicylic acid |
ATE460405T1 (de) * | 2003-07-24 | 2010-03-15 | Merck Sharp & Dohme | Antibiotische verbindung |
-
2005
- 2005-05-20 EP EP05751778A patent/EP1756034B1/en active Active
- 2005-05-20 JP JP2007515205A patent/JP4541405B2/ja active Active
- 2005-05-20 WO PCT/US2005/017832 patent/WO2005115400A2/en not_active Application Discontinuation
- 2005-05-20 US US11/587,074 patent/US7807445B2/en active Active
- 2005-05-20 AU AU2005247434A patent/AU2005247434B2/en active Active
- 2005-05-20 CA CA2565431A patent/CA2565431C/en active Active
- 2005-05-20 CN CN2005800166190A patent/CN1993313B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
WO2005115400A3 (en) | 2006-05-18 |
US7807445B2 (en) | 2010-10-05 |
CN1993313B (zh) | 2012-07-04 |
CA2565431A1 (en) | 2005-12-08 |
EP1756034B1 (en) | 2012-07-04 |
AU2005247434A1 (en) | 2005-12-08 |
EP1756034A2 (en) | 2007-02-28 |
JP4541405B2 (ja) | 2010-09-08 |
US20100144879A1 (en) | 2010-06-10 |
JP2008500343A (ja) | 2008-01-10 |
EP1756034A4 (en) | 2010-06-02 |
AU2005247434B2 (en) | 2011-03-10 |
CA2565431C (en) | 2013-01-15 |
WO2005115400A2 (en) | 2005-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1061095C (zh) | 糖肽抗生素的制备方法 | |
CN1094972C (zh) | 人类来源的乳酸杆菌菌株、它们的组合物及其应用 | |
CN1056883C (zh) | 产生除虫菌素b及其培养物的方法 | |
CN1317384C (zh) | 微生物,获取它的方法及饲料添加剂 | |
Liang et al. | Insect symbionts as valuable grist for the biotechnological mill: an alkaliphilic silkworm gut bacterium for efficient lactic acid production | |
CN1142773A (zh) | 用于控制沙门氏菌的利生菌 | |
CN1133437C (zh) | 诺卡沙星抗菌素 | |
CN101033454A (zh) | 赤红球菌zjb-064及其应用 | |
CN1165547C (zh) | 与阿卡加定相关的新型羊毛硫抗生素及其制备方法和用途 | |
CN1849313A (zh) | 抗生素化合物 | |
CN1993313A (zh) | 抗菌化合物 | |
CN1030470C (zh) | 新抗生素金核霉素的制备方法 | |
CN1880309A (zh) | 新化合物、新菌株、及应用该菌株生产该新化合物的方法 | |
CN1823070A (zh) | 盐孢菌酰胺及其使用方法 | |
KR920003666B1 (ko) | 항생제 a42125 및 이의 제조방법 | |
CN1088983A (zh) | 产生抗寄生化合物的链霉菌属菌株及其制备方法 | |
CN1093371A (zh) | 水生生物革兰氏阳性疾病的治疗 | |
CN1280424C (zh) | 制造d-丝氨酸的方法 | |
CN1031948C (zh) | 抗生素ge2270的制备方法 | |
CN1325453A (zh) | 万古烯霉素、其生产方法及其作为药物的用途 | |
CN1546064A (zh) | 一种防治鸡白痢的冻干微生态制剂 | |
CN87105285A (zh) | 新颖的抗生素及其加成盐 | |
CN86108770A (zh) | 抗菌素tan—749化合物及其制备 | |
JPH0784472B2 (ja) | 抗生物質a80190 | |
CN87102651A (zh) | 抗菌素f-0769及其生产方法和用作生产促进剂、饲料增效剂和抗癌剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SCHERING CORP (US) Free format text: FORMER OWNER: MSD CORP. Effective date: 20121030 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: MSD CORP. Free format text: FORMER NAME: SCHERING CORP (US) |
|
CP01 | Change in the name or title of a patent holder |
Address after: New jersey, USA Patentee after: MERCK SHARP & DOHME Corp. Patentee after: Merck Sharp & Dohme De Espana, S.A. Address before: New jersey, USA Patentee before: SCHERING Corp. Patentee before: Merck Sharp & Dohme De Espana, S.A. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121030 Address after: New jersey, USA Patentee after: SCHERING Corp. Patentee after: Merck Sharp & Dohme De Espana, S.A. Address before: New jersey, USA Patentee before: MERCK SHARP & DOHME Corp. Patentee before: Merck Sharp & Dohme De Espana, S.A. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20220829 Address after: new jersey Patentee after: MERCK SHARP & DOHME B.V. Patentee after: Merck Sharp & Dohme De Espana, S.A. Address before: new jersey Patentee before: MERCK SHARP & DOHME Corp. Patentee before: Merck Sharp & Dohme De Espana, S.A. |
|
TR01 | Transfer of patent right |